OBJECTIVE: To evaluate the effectiveness of the 7-valent pneumococcal conjugate vaccine (PCV7) in preventing pneumonia, diagnosed radiologically according to World Health Organization (WHO) criteria, among indigenous infants in the Northern Territory of Australia. METHODS: We conducted a historical cohort study of consecutive indigenous birth cohorts between 1 April 1998 and 28 February 2005. Children were followed up to 18 months of age. The PCV7 programme commenced on 1 June 2001. All chest X-rays taken within 3 days of any hospitalization were assessed. The primary endpoint was a first episode of WHO-defined pneumonia requiring hospitalization. Cox proportional hazards models were used to compare disease incidence. FINDINGS: There were 526 pneumonia events among 10,600 children - an incidence of 3.3 per 1000 child-months; 183 episodes (34.8%) occurred before 5 months of age and 247 (47.0%) by 7 months. Of the children studied, 27% had received 3 doses of vaccine by 7 months of age. Hazard ratios for endpoint pneumonia were 1.01 for 1 versus 0 doses; 1.03 for 2 versus 0 doses; and 0.84 for 3 versus 0 doses. CONCLUSION: There was limited evidence that PCV7 reduced the incidence of radiologically confirmed pneumonia among Northern Territory indigenous infants, although there was a non-significant trend towards an effect after receipt of the third dose. These findings might be explained by lack of timely vaccination and/or occurrence of disease at an early age. Additionally, the relative contribution of vaccine-type pneumococcus to severe pneumonia in a setting where multiple other pathogens are prevalent may differ with respect to other settings where vaccine efficacy has been clearly established.
OBJECTIVE: To evaluate the effectiveness of the 7-valent pneumococcal conjugate vaccine (PCV7) in preventing pneumonia, diagnosed radiologically according to World Health Organization (WHO) criteria, among indigenous infants in the Northern Territory of Australia. METHODS: We conducted a historical cohort study of consecutive indigenous birth cohorts between 1 April 1998 and 28 February 2005. Children were followed up to 18 months of age. The PCV7 programme commenced on 1 June 2001. All chest X-rays taken within 3 days of any hospitalization were assessed. The primary endpoint was a first episode of WHO-defined pneumonia requiring hospitalization. Cox proportional hazards models were used to compare disease incidence. FINDINGS: There were 526 pneumonia events among 10,600 children - an incidence of 3.3 per 1000 child-months; 183 episodes (34.8%) occurred before 5 months of age and 247 (47.0%) by 7 months. Of the children studied, 27% had received 3 doses of vaccine by 7 months of age. Hazard ratios for endpoint pneumonia were 1.01 for 1 versus 0 doses; 1.03 for 2 versus 0 doses; and 0.84 for 3 versus 0 doses. CONCLUSION: There was limited evidence that PCV7 reduced the incidence of radiologically confirmed pneumonia among Northern Territory indigenous infants, although there was a non-significant trend towards an effect after receipt of the third dose. These findings might be explained by lack of timely vaccination and/or occurrence of disease at an early age. Additionally, the relative contribution of vaccine-type pneumococcus to severe pneumonia in a setting where multiple other pathogens are prevalent may differ with respect to other settings where vaccine efficacy has been clearly established.
Authors: Steven B Black; Henry R Shinefield; Stella Ling; John Hansen; Bruce Fireman; David Spring; Jack Noyes; Edwin Lewis; Paula Ray; Janelle Lee; Jill Hackell Journal: Pediatr Infect Dis J Date: 2002-09 Impact factor: 2.129
Authors: Marilla G Lucero; Hanna Nohynek; Gail Williams; Veronica Tallo; Eric A F Simões; Socorro Lupisan; Diozele Sanvictores; Simon Forsyth; Taneli Puumalainen; Juanita Ugpo; Marites Lechago; Margaret de Campo; Erma Abucejo-Ladesma; Lydia Sombrero; Antti Nissinen; Anu Soininen; Petri Ruutu; Ian Riley; Helen P Mäkelä Journal: Pediatr Infect Dis J Date: 2009-06 Impact factor: 2.129
Authors: Keith P Klugman; Shabir A Madhi; Robin E Huebner; Robert Kohberger; Nontombi Mbelle; Nathaniel Pierce Journal: N Engl J Med Date: 2003-10-02 Impact factor: 91.245
Authors: Jennifer D Loo; Laura Conklin; Katherine E Fleming-Dutra; Maria Deloria Knoll; Daniel E Park; Jennifer Kirk; David Goldblatt; Katherine L O'Brien; Cynthia G Whitney Journal: Pediatr Infect Dis J Date: 2014-01 Impact factor: 2.129
Authors: Amanda Jane Leach; Edward Kim Mulholland; Mathu Santosham; Paul John Torzillo; Ngiare Joy Brown; Peter McIntyre; Heidi Smith-Vaughan; Sue Skull; Anne Balloch; Ross Andrews; Jonathan Carapetis; Joseph McDonnell; Vicki Krause; Peter Stanley Morris Journal: BMJ Open Date: 2015-01-16 Impact factor: 2.692
Authors: Heidi C Smith-Vaughan; Michael J Binks; Jemima Beissbarth; Anne B Chang; Gabrielle B McCallum; Ian M Mackay; Peter S Morris; Robyn L Marsh; Paul J Torzillo; Danielle F Wurzel; Keith Grimwood; Elizabeth Nosworthy; Jane E Gaydon; Amanda J Leach; Barbara MacHunter; Mark D Chatfield; Theo P Sloots; Allen C Cheng Journal: Eur J Clin Microbiol Infect Dis Date: 2018-06-29 Impact factor: 3.267
Authors: Stephen B Gordon; Nigel G Bruce; Jonathan Grigg; Patricia L Hibberd; Om P Kurmi; Kin-bong Hubert Lam; Kevin Mortimer; Kwaku Poku Asante; Kalpana Balakrishnan; John Balmes; Naor Bar-Zeev; Michael N Bates; Patrick N Breysse; Sonia Buist; Zhengming Chen; Deborah Havens; Darby Jack; Surinder Jindal; Haidong Kan; Sumi Mehta; Peter Moschovis; Luke Naeher; Archana Patel; Rogelio Perez-Padilla; Daniel Pope; Jamie Rylance; Sean Semple; William J Martin Journal: Lancet Respir Med Date: 2014-09-02 Impact factor: 30.700